screening for cervical cancer
Jump to navigation
Jump to search
[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34]
Management
Recommendations:
- recommendations for average risk women regardless of sexual history or HPV vaccination status[25]
- begin screening for average risk age women at 25 years (ACS)[1][33]
- women younger than 21 years should not be screened regardless of sexual history[7][9][16][23][25]
- stand-alone HPV testing every 5 years through ages 25-65 years (ACS)[33]
- high risk HPV testing to begin at age 30 years (USPSTF)[1]
- cervical cytology alone every 3 years if HPV testing not available[33]
- women > 65 years of age should not be screened if sufficient previous screening
- women without cervix after hysterectomy should not be screened (see below)[25]
- other screening recommendations
- in a resource-limited setting, women 30-49 years of age can be screened every 10 years with HPV DNA[21]
- for women who have completed HPV vaccination
- screening still recommended[1]
- apparently sceening same with or without HPV vaccination[1]
- screening every 5 years beginning at age 25-30 years with either cytology or HPV DNA testing (bivalent or quadrivalent vaccine)[22]
- screening every 10 years beginning at age 30-35 years with HPV DNA testing[22]
- HPV DNA testing associated with significantly increased detection of high-grade precancerous cervical lesions compared to cytology[25]
- screening still recommended[1]
- women with risk factors may require more frequent screenings:
- if cervical cytology is unsatisfactory, repeat Pap smear
- may discontinue screening at age 65-70[5]
- discontinue screening at age 65 provided sufficient negative screening results
- 3 consecutive negative Pap smears or 2 consecutive negative Pap smears + negative HPV DNA testing[1]
- most recent negative screening test must be within 5 years
- no history of cervical intraepithelial neoplasia grade 2 or higher[9][17]
- discontinue screening at age 65 provided sufficient negative screening results
- older women of any age who have never been screened should be screened until 3 negative Pap smears are obtained 1 year apart (GRS9)[18]*
- issue of including HPV DNA screening discussed inadequately
- do not screen women after hysterectomy with removal of the cervix for benign disease[16] unless history of cervical intraepithelial neoplasia grade 2 or higher,[17] regardless of history of ovarian cancer or endometrial cancer[1]
- bimanual examination not recommended as part of screening[15]
- HPV DNA testing for papillomavirus (cervical specimens)
- outperforms cytology for reducing risk of invasive cervical carcinoma[11]
- negative HPV DNA more predictive than negative cytology for absence of cervical cancer[27]
- because of poor specificity, <A487344>HPV DNA testing</A487344> with cytology is not recommended[1]
- urine specimen potentially an alternative[12]
- HPV testing should not be performed before age 30[16]
- self-collected cervicovaginal samples for HPV testing & STD testing[31]
- screening for chlamydia (Chlamydia DNA) & gonorrhea (Neisseria gonorrhoeae DNA) from urine or self-collected vaginal swabs[15]
Also see recommendations for performing Pap smears
Notes
- 88% of women comply with USPSTF recommendations for screening, yet 47% of cervical cancers present at late stage[6]
- prognoses for women with cervical cancer may be better if detected by screening rather than upon workup of symptoms[8]
- 19 algorithms too complicated to memorize[10]
- HPV vaccination status does not alter recommendations for cervical cancer screening[1]
- cervical cancer screening in average-risk women is still initiated too soon & continued for too long[24]
- women never screened with 1 in 45 risk of developing cervical cancer in their lifetime[30]
- adherence to cytology screening until age 55 lowers risk to 1 in 138; screening until age 70, lower risk to 1 in 160.
- screening up to age 55 with negative cytology with 1 in 440 risk of developing cancer; risk is 1 in 1940 with a negative HPV test, & 1 in 2253 with negative HPV-cytology cotesting[30]
More general terms
Additional terms
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 16, 17, 18. American College of Physicians, Philadelphia 1998, 2006, 2012, 2015, 2018
Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022 - ↑ Brewster WR et al Feasibility of management of high-grade cervical lesions in a single visit: a randomized controlled trial. JAMA. 2005 Nov 2;294(17):2225-8 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16264159
- ↑ Nauclear P et al, Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007, 357:1589 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17942872
- ↑ Bulkmans NWJ et al, Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5 year follow-up of a radomised controlled implementation trial. Lancet 2007, Oct 4 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17919718
- ↑ 5.0 5.1 ACOG PRACTICE BULLETIN CLINICAL MANAGEMENT GUIDELINES FOR OBSTETRICIAN-GYNECOLOGISTS NUMBER 109, DECEMBER 2009 http://journals.lww.com/greenjournal/documents/PB109_Cervical_Cytology_Screening.pdf
ACOG Practice Bulletin Number 131: Screening for cervical cancer. Committee on Practice Bulletins- Gynecology. Obstet Gynecol. 2012;120(5):1222-1238. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23090560 - ↑ 6.0 6.1 Henley SJ et al Surveillance of Screening-Detected Cancers (Colon and Rectum, Breast, and Cervix) --- United States, 2004--2006 Surveillance Summaries Morbidity and Mortality Weekly Report (MMWR) November 26, 2010 / 59(SS09);1-25 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21102407 <Internet> http://www.cdc.gov/mmwr/preview/mmwrhtml/ss5909a1.htm
- ↑ 7.0 7.1 Saslow D et al American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer CA Cancer J Clin. 2012 Mar 14. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22422631 <Internet> http://onlinelibrary.wiley.com/doi/10.3322/caac.21139/pdf
Saslow D et al American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer J Low Genit Tract Dis. 2012 Mar 13. [Epub ahead of print] <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22418039 <Internet> http://onlinelibrary.wiley.com/doi/10.3322/caac.21139/pdf
Moyer VA Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement Annals of Internal Medicine March 14, 2012 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22422943 <Internet> http://www.annals.org/content/early/2012/03/14/0003-4819-156-12-201206190-00424.full (corresponding NGC guideline withdrawn Feb 2018)
Moyer VA Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med. 2012 Jun 19;156(12):880-91 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22711081 (corresponding NGC guideline withdrawn Feb 2018)
Kizer N and Peipert JF Cervical Cancer Screening: Primum Non Nocere Annals of Internal Medicine March 14, 2012 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22422942 <Internet> http://www.annals.org/content/early/2012/03/14/0003-4819-156-12-201206190-00425.full - ↑ 8.0 8.1 Andrae B et al. Screening and cervical cancer cure: Population based cohort study. BMJ 2012 Mar 1; 344:e900. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22381677
- ↑ 9.0 9.1 9.2 Physician's First Watch, Oct 23, 2012 Massachusetts Medical Society http://www.jwatch.org (subcription required)
- ↑ 10.0 10.1 Massad LS et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013 Apr; 121:829 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23635684
Massad LS et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2013 Apr; 17:S1 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23519301 - ↑ 11.0 11.1 Ronco G et al Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. The Lancet, Early Online Publication, 3 November 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24192252 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62218-7/abstract
- ↑ 12.0 12.1 Pathak N et al Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. BMJ 2014;349:g5264 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25232064 <Internet> http://www.bmj.com/content/349/bmj.g5264
- ↑ 13.0 13.1 Benard VB et al Vital Signs: Cervical Cancer Incidence, Mortality, and Screening - United States, 2007-2012 MMWR. Early Release. November 5, 2014 / 63(Early Release);1-6 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm63e1105a1.htm
- ↑ Cervical Cancer Screening Guidelines for Average-Risk Women. 2012. American Cancer Society (ACS), American Society for Colposcopy and Cervical Pathology (ASCCP), and American Society for Clinical Pathology http://www.cdc.gov/cancer/cervical/pdf/guidelines.pdf
- ↑ 15.0 15.1 15.2 Bloomfield HE, Olson A, Wilt TJ. Screening pelvic examinations in asymptomatic, average-risk adult women. Ann Intern Med. 2014 Dec 16;161(12):924-5 PMID: https://www.ncbi.nlm.nih.gov/pubmed/25506863
Bloomfield HE, Olson A, Greer N et al Screening pelvic examinations in asymptomatic, average-risk adult women: an evidence report for a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014 Jul 1;161(1):46-53. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24979449
Qaseem A, Humphrey LL, Harris R et al Screening pelvic examination in adult women: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014 Jul 1;161(1):67-72. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24979451
Sawaya GF, Jacoby V. Screening pelvic examinations: right, wrong, or rite? Ann Intern Med. 2014 Jul 1;161(1):78-9. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24979453 - ↑ 16.0 16.1 16.2 16.3 Sawaya GF et al Cervical Cancer Screening in Average-Risk Women: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. Published online 30 April 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25928075 <Internet> http://annals.org/article.aspx?articleid=2281177
Wilt TJ, Harris RP, Qaseem A for the High Value Care Task Force of the American College of Physicians. Screening for Cancer: Advice for High-Value Care From the American College of Physicians. Ann Intern Med. 2015;162(10):718-725. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25984847 <Internet> http://annals.org/article.aspx?articleid=2294149
Harris RP, Wilt TJ, Qaseem A for the High Value Care Task Force of the American College of Physicians. A Value Framework for Cancer Screening: Advice for High-Value Care From the American College of Physicians. Ann Intern Med. 2015;162(10):712-717 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25984846 <Internet> http://annals.org/article.aspx?articleid=2293237 - ↑ 17.0 17.1 17.2 Young K, Fairchild DG, Di Francesco L ACOG Offers New Cervical Cancer Screening Recommendations Physician's First Watch, Dec 23, 2015 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org ACOG Practice Bulletin (subscription required)
- ↑ 18.0 18.1 Geriatric Review Syllabus, 9th edition (GRS9) Medinal-Walpole A, Pacala JT, Porter JF (eds) American Geriatrics Society, 2016
- ↑ Castle PE, Fetterman B, Poitras N et al Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol. 2009 Mar;113(3):595-600. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19300322 Free PMC Article
- ↑ Dijkstra MG et al Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. BMJ 2016;355:i4924 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27702796 Free full text <Internet> http://www.bmj.com/content/355/bmj.i4924
- ↑ 21.0 21.1 Jeronimo J, Castle PE, Temin S et al Secondary Prevention of Cervical Cancer: ASCO Resource- Stratified Clinical Practice Guideline. Journal of Global Oncology. Oct 12, 2015 Not indexed in PubMed http://jgo.ascopubs.org/content/early/2016/10/08/JGO.2016.006577.full
Jeronimo J, Castle PE, Temin S, Shastri SS. Secondary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary. J Oncol Pract. 2016 Nov 15:JOP2016017889. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27845871
Castle PE, Jeronimo J, Temin S, Shastri SS. Screening to Prevent Invasive Cervical Cancer: ASCO Resource- Stratified Clinical Practice Guideline. J Clin Oncol. 2017 Jan 30:JCO2016716563. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28135111 - ↑ 22.0 22.1 22.2 Kim JJ, Burger EA, Sy S, Campos NG Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus. J Natl Cancer Inst (JNCI). 2017 Feb;109(2). online Oct 17, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27754955 <Internet> http://jnci.oxfordjournals.org/content/early/2016/10/17/jnci.djw216.abstract
- ↑ 23.0 23.1 American Society for Colposcopy and Cervical Pathology Choosing Wisely. February 14, 2017 http://www.choosingwisely.org/societies/american-society-for-colposcopy-and-cervical-pathology/
- ↑ 24.0 24.1 Teoh D et al. Single health system adherence to 2012 cervical cancer screening guidelines at extremes of age and posthysterectomy. Obstet Gynecol 2017 Mar; 129:448 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28178049 <Internet> http://insights.ovid.com/crossref?an=00006250-201703000-00007
- ↑ 25.0 25.1 25.2 25.3 25.4 Canfell K, Caruana M, Gebski V et al Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. PLOS Medicine. September 19, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28926579 <Internet> http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002388
- ↑ U.S. Preventive Services Task Force (USPSTF) Draft Recommendation Statement. Cervical Cancer: Screening. https://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/cervical-cancer-screening2
- ↑ 27.0 27.1 Castle PE, Kinney WK, Xue X et al. Effect of several negative rounds of human papillomavirus and cytology co-testing on safety against cervical cancer: An observational cohort study. Ann Intern Med 2017 Nov 28; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29181509
Ronco G, Franceschi S. Cervical cancer screening: The transformational role of routine human papillomavirus testing. Ann Intern Med 2017 Nov 28 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29181508 - ↑ Ogilvie SG, van Niekerk D, Krajden M et al Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months. The HPV FOCAL Randomized Clinical Trial. JAMA. 2018;320(1):43-52 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29971397 https://jamanetwork.com/journals/jama/fullarticle/2686793
Massad LS Replacing the Pap Test With Screening Based on Human Papillomavirus Assays. JAMA. 2018;320(1):35-37 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29971379 https://jamanetwork.com/journals/jama/fullarticle/2686771 - ↑ US Preventive Services Task Force Screening for Cervical CancerUS Preventive Services Task Force Recommendation Statement JAMA. 2018;320(7):674-686. Aug 21, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30140884 https://jamanetwork.com/journals/jama/fullarticle/2697704
Melnikow J, Henderson JT, Burda BU et al US Preventive Services Task Force, Evidence Report Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing. Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018;320(7):687-705. August 21, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30140883 https://jamanetwork.com/journals/jama/fullarticle/2697703
Kim JJ, Burger EA, Regan C et al US Preventive Services Task Force. Modeling Study Screening for Cervical Cancer in Primary Care. A Decision Analysis for the US Preventive Services Task Force. JAMA. 2018;320(7):706-714. August 21, 2018 MID: 30140882 https://jamanetwork.com/journals/jama/fullarticle/2697702
Learman LA, MD, Garcia FAR Screening for Cervical CancerNew Tools and New Opportunities. JAMA. 2018;320(7):647-649. August 21, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30140859 https://jamanetwork.com/journals/jama/fullarticle/2697678
Sawaya GF Cervical Cancer Screening - Moving From the Value of Evidence to the Evidence of Value. JAMA Intern Med. Published online August 21, 201 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30140917 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2697768 - ↑ 30.0 30.1 30.2 Malagon T, Kulasingam S, Mayrand MH et al Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study. Lancet Oncology. Nov 01, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30392810 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30536-9/fulltext
- ↑ 31.0 31.1 Des Marais AC, Zhao Y, Hobbs MM et al. Home self-collection by mail to test for human papillomavirus and sexually transmitted infections. Obstet Gynecol 2018 Nov 5; 132:1412. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30399091 https://insights.ovid.com/crossref?an=00006250-900000000-97873
- ↑ ARUP Consult: Human Papillomavirus (HPV) Testing - Cervical Cancer Screening The Physician's Guide to Laboratory Test Selection & Interpretation https://www.arupconsult.com/content/human-papillomavirus
- ↑ 33.0 33.1 33.2 33.3 Fontham ETH , Wolf AMD Church TR et al Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70:321-346. July 30 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32729638 https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21628
- ↑ Perkins RB, Guido RS, Castle PE et al 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020 Apr;24(2):102-131. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32243307 PMCID: PMC7147428 Free PMC article.